Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
+$2.7B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.39B |
| 3 |
AbbVie
ABBV
|
+$1.95B |
| 4 |
Wells Fargo
WFC
|
+$1.03B |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$1.03B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Trip.com Group
TCOM
|
+$546M |
| 2 |
KRFT
KRAFT FOODS GROUP INC COM STK (VA)
KRFT
|
+$274M |
| 3 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$273M |
| 4 |
Home Depot
HD
|
+$257M |
| 5 |
Progressive
PGR
|
+$246M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 30.23% |
| 2 | Healthcare | 10.87% |
| 3 | Financials | 9.03% |
| 4 | Technology | 8.57% |
| 5 | Consumer Discretionary | 7.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6276
Aurinia Pharmaceuticals
AUPH
$2.22B
| $3K | ﹤0.01% |
1,055
+1,002
| +1,891% | +$3.72K |
2014 Q3
3 quarters
|
|
6277
Virtus Biotech Clinical Trials ETF
BBC
$41.9M
| $3K | ﹤0.01% |
70
-100
| -59% | -$3.44K |
2015 Q1
1 quarter
|
|
6278
Comstock Holding Companies
CHCI
$192M
| $3K | ﹤0.01% |
719
+143
| +25% | +$687 |
2013 Q4
6 quarters
|
|
6279
Comp X International
CIX
$484M
| $3K | ﹤0.01% |
254
-134
| -35% | -$1.57K |
2013 Q4
6 quarters
|
|
6280
CKX Lands
CKX
$21.4M
| $3K | ﹤0.01% |
200
| – | – |
2013 Q4
6 quarters
|
|
6281
Crown Crafts
CRWS
$25.7M
| $3K | ﹤0.01% |
359
-307
| -46% | -$2.49K |
2013 Q4
6 quarters
|
|
6282
Bio Green Med Solution Inc
BGMS
$5.62M
| – | – |
0
| – | – |
2013 Q2
8 quarters
|
|
6283
iPath Bloomberg Commodity Index Total Return ETN due 12 June 2036
DJP
$884M
| $3K | ﹤0.01% |
96
-16,828
| -99% | -$485K |
2013 Q2
8 quarters
|
|
6284
Cambria Foreign Shareholder Yield ETF
FYLD
$718M
| $3K | ﹤0.01% |
135
| – | – |
2014 Q2
4 quarters
|
|
6285
JPMorgan Diversified Return International Equity ETF
JPIN
$374M
| $3K | ﹤0.01% |
+65
| New | +$3.47K |
2015 Q2
0 quarters
|
|
6286
ProShares UltraShort Bloomberg Natural Gas
KOLD
$133M
| $3K | ﹤0.01% |
11
-289
| -96% | -$78K |
2014 Q1
5 quarters
|
|
6287
Riot Platforms
RIOT
$6.34B
| $3K | ﹤0.01% |
759
+15
| +2% | +$64 |
2013 Q2
8 quarters
|
|
6288
Sify Technologies
SIFY
$931M
| $3K | ﹤0.01% |
302
+133
| +79% | +$1.13K |
2013 Q4
6 quarters
|
|
6289
DELISTED
Sonnet BioTherapeutics
SONN
| – | – |
0
| – | – |
2014 Q1
5 quarters
|
|
6290
DELISTED
Strata Skin Sciences
SSKN
| $3K | ﹤0.01% |
45
-1
| -2% | -$81 |
2013 Q4
6 quarters
|
|
6291
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $3K | ﹤0.01% |
35
+1
| +3% | +$82 |
2014 Q1
5 quarters
|
|
6292
DELISTED
ENGlobal Corp
ENG
| $3K | ﹤0.01% |
300
-625
| -68% | -$7.65K |
2013 Q4
6 quarters
|
|
|
AAU
6293
DELISTED
Almaden Minerals Ltd
AAU
| $3K | ﹤0.01% |
3,800
+1,600
| +73% | +$1.36K |
2013 Q2
8 quarters
|
|
|
APTO
6294
DELISTED
Aptose Biosciences, Inc.
APTO
| $3K | ﹤0.01% |
1
| – | – |
2014 Q4
2 quarters
|
|
6295
DELISTED
Reeds, Inc. Common Stock
REED
| $3K | ﹤0.01% |
10
| – | – |
2013 Q3
7 quarters
|
|
|
AATC
6296
DELISTED
Autoscope Technologies Corporation Common Stock
AATC
| $3K | ﹤0.01% |
809
+9
| +1% | +$27 |
2014 Q1
5 quarters
|
|
|
INWK
6297
DELISTED
InnerWorkings, Inc.
INWK
| $3K | ﹤0.01% |
485
-2,615
| -84% | -$17.1K |
2013 Q2
8 quarters
|
|
|
MJCO
6298
DELISTED
Majesco
MJCO
| $3K | ﹤0.01% |
+491
| New | +$2.5K |
2015 Q2
0 quarters
|
|
6299
DELISTED
Dermira, Inc.
DERM
| $3K | ﹤0.01% |
+195
| New | +$3.01K |
2015 Q2
0 quarters
|
|
|
MELR
6300
DELISTED
Melrose Bancorp, Inc.
MELR
| $3K | ﹤0.01% |
206
+1
| +0.5% | +$14 |
2014 Q4
2 quarters
|
|
Similar funds
Morgan Stanley's Q2 2015 Portfolio in Review
As of Q2 2015, Morgan Stanley held 7,065 positions worth $289B, up 6.3% from $272B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Morgan Stanley deployed $19B of net new capital in Q2 2015, opening 213 new positions and adding to 3,439 existing holdings. Its largest new stake was EQGP Holdings, LP: 2,862,984 shares worth $97.3M.
By sector, the portfolio is most concentrated in Miscellaneous at 30% of assets, up from 30% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Trip.com Group, an estimated $546M trimmed.
- Morgan Stanley's largest Q2 2015 buy was EQGP Holdings, LP: 2,862,984 shares worth $97.3M.
- Morgan Stanley added most to Express Scripts Holding Company in Q2 2015, an estimated $2.7B increase.
- Morgan Stanley's biggest Q2 2015 reduction was Trip.com Group, cutting an estimated $546M.
- Morgan Stanley fully exited LORILLARD INC COM STK in Q2 2015, selling an estimated $162M.
- Morgan Stanley's ten largest holdings make up 12% of its $289B portfolio in Q2 2015.
- Morgan Stanley opened 213 new positions and closed 120 in Q2 2015.
- Morgan Stanley's portfolio value rose 6.3% quarter-over-quarter to $289B.
Based on Morgan Stanley's 13F filing for Q2 2015, filed 12 Aug 2015.